AXQ Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

AXQ Capital’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,326	Closed	-$38.5K	–	1252
2026 Q1	$38.5K	Buy	+11,326	New	+$38.4K	0.01%	942

Other funds holding ORMP

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AXQ Capital's ORMP Position: Q2 2026 in Review

AXQ Capital sold out of Oramed Pharmaceuticals (ORMP) in Q2 2026, closing a stake of 11,326 shares — an estimated $38.5K sold.

AXQ Capital first reported a position in ORMP in Q1 2026 and held it in 1 quarter. The position peaked at $38.5K in Q1 2026. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

AXQ Capital reported no remaining Oramed Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
AXQ Capital sold 11,326 Oramed Pharmaceuticals shares in Q2 2026, an estimated $38.5K.
AXQ Capital first reported a position in Oramed Pharmaceuticals in Q1 2026 and held it in 1 quarter.
AXQ Capital's Oramed Pharmaceuticals position peaked at $38.5K in Q1 2026.
84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.